Pfizer (PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results. The study met its primary endpoint, with tilrekimig showing a ...
When Is the Right Time? A Qualitative Study of Timing of Specialty Palliative Care in Patients With Brain Tumors Phase II trials are intended to identify promising treatment paradigms for definitive ...
Immune Checkpoint Inhibitors in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Chemotherapy-Naïve Advanced Non–Small Cell Lung Cancer: A Meta-Analysis Based on Eight Randomized ...
FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HITPhase 2 data showed a greater than 25% absolute reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results